AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st.
|Event:||Piper Sandler 34th Annual Healthcare Conference – November 29th – December 1st|
|Presentation:||Lumos Pharma Fireside Chat November 30th at 2:00-2:25 PM (EST)|
|1×1 Meetings:||Management will be available for one-on-one meetings on November 30th|
The webcast for the presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your Piper Sandler salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lumos Pharma Investor Relations
Source: Lumos Pharma, Inc.
- Receivables Performance Management Data Breach Alert: Issued by Wolf Haldenstein Adler Freeman & Herz LLP - November 28, 2022
- Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q - November 28, 2022
- P10 Scheduled to Ring the Opening Bell at New York Stock Exchange - November 28, 2022